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Microbiome insights into pediatric familial
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Thomas M. Attard1, Seth Septer2, Caitlin E. Lawson3, Mark I. Attard4, Sonny T. M. Lee5 and Shahid Umar6*   

Abstract
Background: Individuals with familial adenomatous polyposis (FAP) harbor numerous polyps with inevitable early
progression to colon cancer. Complex microbiotic-tumor microenvironment perturbations suggest a dysbiotic
relationship between polyp and microbiome. In this study, we performed comprehensive analyses of stool and tissue
microbiome of pediatric FAP subjects and compared with unaffected cohabiting relatives through 16S V4 region
amplicon sequencing and machine learning platforms.
Results: Within our FAP and control patient population, Firmicutes and Bacteroidetes were the predominant phyla in
the tissue and stool samples, while Proteobacteria dominated the polyp/non-polyp mucosa. A decline in Faecalibacterium in polyps contrasted with a decline in Bacteroides in the FAP stool. The alpha- and beta-diversity indices differed
significantly within the polyp/non-polyp groups, with a concurrent shift towards lower diversity in polyps. In a limited
3-year longitudinal study, the relative abundance of Proteobacteria and Fusobacteria was higher in polyps compared
to non-polyp and stool specimens over time. Through machine learning, we discovered that Archaeon_enrichment_
culture_clone_A13, Micrococcus_luteus, and Eubacterium_hallii in stool and PL-11B10, S1-80, and Blastocatellaceae in
tissues were significantly different between patients with and without polyps.
Conclusions: Detection of certain bacterial concentrations within stool or biopsied polyps could serve as adjuncts to
current screening modalities to help identify higher-risk patients.
Keywords: Familial adenomatous polyposis, Colorectal cancer, Microbiome
Introduction
Colorectal cancer (CRC) is one of the most common
malignancies worldwide and the third leading cause of
cancer in the United States. Most cases of CRC are sporadic, but a clear familial predisposition is evident in up
to 30% of individuals, with another 5% presenting in individuals with a cancer-predisposing syndrome [1].
Familial Adenomatous Polyposis (FAP) is a hereditary
predisposition for the development of numerous colorectal adenomas that inevitably progress to colorectal
cancer in early adulthood [2]. The underlying genetic
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abnormality resides in a mutation of the APC gene on
chromosome 5q21. Affected individuals harbor germline
mutation coding for a truncated protein and then acquire
a second mutation that inactivates APC protein synthesis. This results in decreased intracellular Beta-catenin
clearance and subsequent activation of the Wnt-wingless
pathway that modulates cell polarity, migration, and proliferation. Although it is relatively uncommon (incidence;
1:8,000) the mechanisms driving tumorigenesis in FAP
are virtually identical to the great majority of patients
with sporadic colorectal cancer so that observations on
microbiome and polyp interrelationships may have significant implications to the vast CRC burden in the general population.
Microbiota modulation of cellular physiology is
thought to play a critical role both in health and
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disease, most notably in gastrointestinal illnesses including inflammatory bowel disease [3], including in children
[4], and in cancer. The observed relationships include
patterns of changes in specific bacterial subgroups or in
measures of the diversity of the bacterial population in
both healthy and diseased tissue or stool from affected
individuals compared to healthy controls.
The discovery of a relationship between Streptococcus bovis endocarditis and CRC [5] paved the way for
a trove of research ranging from in vitro, in-vivo, and
subsequent human epidemiologic and metagenomics
research [6]. Colorectal regional differences and more
intimately biofilm-mediated specific interactions have
demonstrated that the tumor microenvironment may
be polyp [7] and site-specific. Pro- and anti-neoplastic
bacterial species and phyla have emerged with sub-networks of co-occurring and co-excluding microbes at and
around neoplastic sites [8]. The proposed mechanisms
include bacterial oncoproteins, metabolite interaction
with oncogenic pathways, and inflammatory mediators
that indirectly modulate cell proliferation and apoptosis.
The modulating effects of the microbiome may in part be
associated with microenvironmental factors that influence adenoma progression and tumor development.
Our hypothesis was that mucosal-level microbiome
influences and is influenced by polyp development in
individuals with FAP. We postulate that differences we
observe in the microbiome constitution of non-polyp and
polyp mucosa reflects the microbiome characteristics
that favor polyp growth, our aim therefore is to describe
the permutations in microbiome between polyp and nonpolyp mucosa in children with FAP with a secondary aim
of comparing both with fecal derived microbiome.
Children with FAP represent a population at risk as
well as a paradigm for the high likelihood of adenoma
development with the potential to shed new insight on
the mechanism of both syndromic and sporadic CRC
tumorigenesis and metagenomics. Observations in
this population may therefore have significant broader
ramifications.

Materials and methods
Patient recruitment

The study was reviewed and approved, designated as no
greater than minimal risk, by the institutional IRB of the
participating site (Children’s Mercy Kansas City IRB#
13120420), subjects consented to participate or, if minor
assented to participate in the study, with consent from their
respective legal guardians prior to enrollment. All methods
were performed in accordance with the relevant guidelines
and regulations. Thirteen patients (7 Male) with FAP followed at the Multidisciplinary Clinic at Children’s Mercy
Hospital were recruited along with unaffected cohabiting
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family members designated as controls. Diagnosis of FAP
was based on published, standard clinical criteria for children, genetic testing results were noted, when available.
Neither subjects nor controls had received antibiotics up
to two weeks pre-procedure, although one subject had
received probiotics. Their mean age (SD) at the time of
polyp/tissue sampling was 13.7 (3.31) years, and the cohort
included two sibling pairs. Adenomatous polyps, defined
as intraluminal projecting lesions measuring > 3–5 mm
in diameter estimated by two experienced endoscopists
(TMA, SS), were removed and submitted as polyp tissue along with a biopsy of normal-appearing (non-polyp)
mucosa (natural and digital image enhanced endoscopy
(IEE) distant to the polyp but within the same colorectal
anatomic segment. A corresponding stool specimen was
obtained within a week prior to the endoscopy and not
from the time of pre-colonoscopy prep, was obtained and
paired with a stool specimen in a prior determined unaffected sibling. Overall, 50 separate samples (25 tissue, 25
stool) were successfully submitted and processed (Table 1).
In 4 samples, labelling was found to be incomplete; these
samples were included only in the pooled analysis depending on the known parameters that were recorded (e.g., tissue undifferentiated; polyp or non-polyp mucosa, subject 3,
1st year, subject 5, 1st and 2nd year) (Table 2). Three subjects were referred to colectomy during the study period,
although this was not an exclusion parameter.
Table 1 Subject and control demographic characteristics
Subject/control

Subject

Control

Gender

Age at
procedure

Gender

Age

1

F

19

F

43

2

F

16

F

51

3

F

17

F

48

4

F

17

F

49

19
5

M

10

51
M

11

13
14

12

15

6

M

9

F

29

7

F

12

M

45

8

M

6

9

M

15

10

M

14

F

50

7
16
15

50

11

F

12

F

49

12

M

15

F

49

13

M

12

F

49
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Table 2 Samples

Stool and tissue processing, bioinformatic and statistical
analysis

Fecal specimens and adenomatous/normal tissues from
FAP and non-FAP control subjects were collected and
immediately frozen and stored at − 80 °C. DNA was
extracted using a Power Soil Kit (MO Bio). The 16S V4

region was amplified using 515F/806R primers and
sequenced using amplicon sequencing on IonS5TMXL to
generate raw reads. Paired-end reads were assigned to
samples based on their unique barcode and truncated by
cutting off the barcode and primer sequences. We used
Cutadapt [9] (V2.1, http://cutadapt.readthedocs.io/en/
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stable/) with parameters p-error-rate 0.1 to remove primers and adaptors from the sequences before performing downstream bioinformatic processes in QIIME2 v
2020.8.0. Briefly, we used QIIME2-wrapped DADA2
v1.14 (Callahan BJ, 2016) to remove chimeric and singleton sequences and join paired-end reads to provide
the Operational Taxonomic Unit (OTU) table. The reads
were compared with the Silva 132 (https://www.arb-silva.
de/) [10] using pre-trained classifiers from QIIME2 data
resources.
To study phylogenetic relationships of different OTUs,
and the difference of the dominant species in different
samples (groups), multiple sequence alignments were
conducted using QIIME2. OTUs abundance information was normalized using a standard sequence number
corresponding to the sample with the least sequences.
Subsequent analyses of alpha diversity and beta diversity
were all performed based on this output normalized data.
Alpha diversity was applied in analyzing the complexity of species diversity for a sample through six indices,
including Observed-species, Chao1, Shannon, Simpson,
ACE, and Good-coverage. All these indices in our samples were calculated with QIIME2 and displayed with
R software (Version 2.15.3). Beta diversity analysis was
used to evaluate differences of samples in species complexity. Beta diversity on both weighted and unweighted
unifrac were calculated by QIIME2. Principal Coordinate
Analysis (PCoA) was performed to get the principal coordinates and for visualization of the complex, multidimensional data. A distance matrix of weighted or unweighted
unifrac among samples obtained before was transformed
to a new set of orthogonal axes, by which the maximum
variation factor was demonstrated by the first principal
coordinate, and the second maximum one by the second
principal coordinate, etc. PCoA analysis was displayed
by WGCNA package, stat packages, and ggplot2 package
in R software (Version 2.15.3). Unweighted Pair-group
Method with Arithmetic Means (UPGMA) Clustering was performed as a type of hierarchical clustering
method to interpret the distance matrix using average
linkage and was conducted by QIIME2. Statistical analysis was performed using PERMANOVA, t test, Wilcox
and Tukey test in R Adonis package. We also use LEfSe
and ANOSIM to determine if there were any statistical
differences in the microbial composition between the
FAP individuals and the control populations.
Machine learning

We divided the cohort stool samples into training and
validation sets (Additional file 3: Table S1). The training
set consisted of six samples from controls with no polyps
and seven samples from patients with polyposis. The validation set consisted of five samples from controls with
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no polyps and eight samples from patients with polyposis. We evaluated the training set with three different
algorithms, representing simple and complex nonlinear
methods: k-Nearest Neighbors (KNN), Support Vector
Machines (SVM) with a linear kernel and Random Forest
(RF). The caret package (Ver 6.0.86) was used in Rstudio
Version 1.3.1073 using R Version 4.0.2. We chose the best
algorithm on the basis of accuracy and kappa, after fivefold cross-validation with five repeats (Additional file 4:
Table S2).

Results
Study population

The study cohort included 13 individuals under the age
of 21 with clinically diagnosed FAP; the demographic
characteristics of the study population are summarized in
Table 1. Seven subjects were male, the mean (SD) age was
13.4 (3.7) years at the initial procedure. Table 2 summarizes the samples that were obtained and included in this
study. Table 3 summarizes the subject genetic mutation
testing, colonic polyp burden at the time of the sampling
procedure and outcome defined by referral to colectomy
within the follow-up period (2 years) from study completion. Most patients had an identified APC gene mutation,
although had three tested negative on prior, early generation APC testing. Polyp burden varied across the cohort
with no clear progression with time in those individuals
sampled repeatedly. None of the study participants had
polyps estimated larger than one cm in diameter; most
(79%) were categorized < 5 mm. The initial (study) procedure was followed by colectomy in three patients within a
2-year follow-up observation period.
Differential regulation of gut microbiota in polyp
versus non‑polyp and fecal samples

The gut microbiota profile was the single primary endpoint of the present study. On average, ~ 1450 bacterial
OTUs were detected in stool or tissue samples combined (Additional file 1: Fig. S1A). The top 10 phyla
in the different taxonomic ranks including Firmicutes
(40.6 ± 12.1%), Bacteroidetes (43.6 ± 11.6%), Proteobacteria (10.3 ± 11.9%), Actinobacteria (3.2 ± 1.7%), Fusobacteria (0.9 ± 1.1%), Verrucomicrobia (0.6 ± 0.7%),
Cyanobacteria (0.3 ± 0.4%), Euryarchaeota (0.1 ± 0.1%),
Acidobacteria (0.1 ± 0.1%) and Chloroflexi (0.1 ± 0.1%)
formed the distribution histogram of relative abundance (Fig. 1A). The bacterial flora analysis showed
that Firmicutes and Bacteroidetes were the predominant phyla of the tissue/stool microbiota in healthy or
patients with polyps, respectively. In both the adenomatous polyp biopsy (P) and the adjacent non-polyp
mucosa (H) however, the dominant phylum was Proteobacteria (P:19.5 ± 8.7%; H:20.1 ± 15.6%) compared
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Table 3 Clinical characteristics of study subjects, colonoscopy findings, polyp burden and follow up (colectomy at 2 years)
Subject

Subject

Study year

Gender

Age

APC mutation

1

F

19

POSITIVE

2

F

16

UNKNOWN

3

F

17

4

F

17

M

10

Outcome

Number

Size
distribution/
mm

Distribution

Colectomy (age)

1

6–10

<5

A,D

N

1

11–15

<5

PC

N

4720delA

1

<5

<5

A,S,R

N

POSITIVE

1

<5

5–10

D,R

N

3

21–30

<5

C,A,D,S,R

1

6–10

<5

D,S,R

2

5–10

<5

C,A,D,S,R

19
5

Polyp burden

3183del5

11
12

N

3

<5

<5

C,A,D,S

6

M

9

PV in promoter 1B region

1

6–10

<5

D,S,R

N

7

F

12

453delA

1

6–10

<5

T,D,S

N

8

M

6

Large deletion in the APC gene

1

16–20

<5

PC

N

2

31–50

<5

PC

N

3

31–50

<5

A,T,D,S,R

1

6–10

<5

A,D,S,R

2

16–20

<5

S,R

7
9

M

15

2
POSITIVE

16
10

M

14

UNKNOWN

15

N

11

F

12

NEGATIVE

1

12

M

15

NEGATIVE

1

> 50

5–10

PC

Y(15)

13

M

12

NEGATIVE

1

11–15

<5

PC

Y(14)

to that found in stool samples from patients with polyps (S:1.7 ± 0.5%) or healthy subjects (HS:1.5 ± 1.1%)
(Fig. 1A, B). Interestingly, the decline in relative abundance of Bacteroidaceae in the stool samples of FAP
patients was more dramatic (Fig. 1B), suggesting that
decreases in Bacteroidaceae relative abundance in stool
may follow those recorded in adenomatous polyp or
adjacent non-polyp mucosa.
When bacteria were agglomerated at the class,
order, family, and genus levels, Gammaproteobacteria (7.0 ± 10.3%), Enterobacteriales (6.2 ± 9.6%),
Enterobacteriaceae (6.2 ± 9.6%), and E. coli-Shigella
(4.7 ± 7.6%) clusters predominantly represented
the Proteobacteria phyla. Other significant changes
recorded were a decline in the relative abundance of
Bifidobacteriaceae belonging to Actinobacteria and
Clostridia, Lachnospiraceae and Faecalibacterium

Y(13)

belonging to the Firmicutes phyla (Fig. 1, Additional
file 2: Figs. S1B–S1E). Interestingly, the presence of
Fusobacteria was barely detected in the stools of either
patient or healthy subjects (Fig. 1).
α‑Diversity of gut microbiota in stool and tissue samples

Figure 2 shows the α-Diversity indices (observed species),
which represent the richness and sequencing depth, and
Simpson index that represents diversity within a sample.
Overall, the bacterial diversity was significantly different among the samples (Fig. 2A, B). Adjacent non-polyp
mucosa exhibited significant differences in microbiome
diversity from polyps (P), adjacent non-polyp mucosa
(H), stool (S) samples from subjects, and healthy controls
(HS). (Fig. 2A, B). Venn diagrams representing the intersection of various microbiome taxonomic levels between
datasets revealed 2022(P), 58(S), 431(HS), and 801(H)

(See figure on next page.)
Fig. 1 Changes in the relative abundance of top 10 phyla. Stool samples or biopsies were collected from healthy subjects or those with polyps
every year for 3 years, followed by 16S gene sequencing. A Phylum relative abundance heatmap. The heatmaps displaying relative abundance
distribution of dominant phyla among samples. B Relative abundance in specified groups. Histogram showing relative abundance in indicated
groups. Arrows showing significant changes in indicated phyla. C Relative abundance in specified groups. Box plots showing the relative
abundance of Firmicutes, Bacteroidetes, and Proteobacteria in specified groups. Wilcoxon rank-sum tests of the relative abundances, with P < 0.05 and
detected in at least 70% of the samples, are shown
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Fig. 2 Variation analysis of alpha and beta diversity indices within and between groups. Alpha diversity indices of indicated samples showing
observed OTUs (A), and Simpson (B) indices, respectively. C. Venn and Flower diagram. Venn diagrams showing shared and unique OTUs at 97%
identity among the indicated groups. D Non-metric multidimensional scaling (NMDS). NMDS plot of tissues/stool bacterial community structure in
the indicated groups. E Detailed ANOSIM analyses of most significant differences amongst groups. ANOSIM analysis was done for the comparison
of β diversity. The y-axis represents the distance rank between samples, and the x-axis represents the results between both groups. R and P values
are as indicated, with positive R values corresponding to significant differences supported by P values
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unique OTUs, while 1791 overlapping OTUs were shared
by all the four groups (Fig. 2C). Predominant phyla
belonging to these OTUs were Firmicutes, Cyanobacteria, and Proteobacteria, respectively.
β‑Diversity of gut microbiota in stool and tissue samples

Non-metric multidimensional scaling (NMDS; stress
0.145) revealed significant alignment of P with H samples
(Fig. 2D). NMDS for S or HS samples aligned together
but clustered separately from either P or H samples,
indicating clear site-specific differences in the microbial
distribution in tissue and distant stool samples (Fig. 2D).
Specifically, NMDS exhibited significant alignment of
microbial communities in tissue or stool samples from
FAP patients suggesting clearly that polyp and stool
microbiomes are very distinct. Systematic group-wise
comparison with a non-parametric permutation analysis
of similarity (ANOSIM) confirmed that significant separation occurred between tissue and stool samples among
groups at the level of R ranging between 0.35 (S vs. P;
p = 0.001) to 0.391 (HS vs. P; p = 0.001) indicating that
inter-group differences were greater than intra-group
differences in microbial profile while ANOSIM revealed
no significant separation within a patient between H or
P group (Fig. 2E). Unweighted Pair-group Method with
Arithmetic Mean (UPGMA) clustering algorithm on the
weighted or unweighted UniFrac distances of samples
further highlighted the segregation of bacterial communities in the tissue or stool samples (Fig. 3A, B).
We used LEfSe [11] and highlighted marked differences in the predominance of bacterial communities
among groups (Fig. 3C). LEfSe plot displayed LDA scores
of microbial taxa with significant differences in the tissue and stool samples not only within a patient but also
between healthy subjects with the predominance of
Alpha-/β-Proteobacteria, E. coli-Shigella, Fusobacteria and Bacteroidaceae (P), Gammaproteobacteria (H),
and Clostridia and Negativicutes (S) at the class level
and Alistepis genus belonging to the Bacteroidetes phyla
(HS; Fig. 3C). These findings were corroborated by cladogram using the export2graphlan script provided with
GraPhlAn that highlighted the differences in relative
abundance among groups (Fig. 3C).
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Machine learning algorithms to identify bacterial
communities

Amongst three machine learning models, the random
forest (RF) model emerged, yielding the highest mean
accuracy (0.81) and mean kappa values (0.64) on the
training samples. This was applied to the validation samples to classify patients with FAP from controls. There
were no misclassifications with a statistically significant
accuracy metric. The top ten bacterial populations representing the most important variables in the RF model
were assessed for correlations to patients with FAP
(Fig. 4). We observed that Archaeon enrichment culture
clone A13, Micrococcus luteus, and Eubacterium hallii distinguished stool from patients with and without
polyposis (controls) (Fig. 4). We also observed that while
the RF model was unable to predict non-polyp mucosa
from polyp tissue in affected individuals at species and
genus level, the accuracy was significantly higher at the
family level. Bacteria from the three families—PL-11B10,
S1-80, and Blastocatellaceae, were significantly different
between patients with and without polyposis.
Differential regulation in longitudinal study

A subset of the samples was analyzed longitudinally to
determine if microbiome changes could be seen in multiple years of polyposis. We observed a gradual increase in
Proteobacteria in polyps in years 1–3 (P1-P3) and in adjacent non-polyp mucosa (H1-H3) samples, respectively
(Fig. 5A). In contrast, Proteobacteria levels in P1-P3
were negligible when measured in stool samples of either
FAP patients or healthy subjects, clearly eliciting differences in the two sites (Fig. 5A). Firmicutes, on the other
hand, declined from P1 to P3 or H1-H3, suggesting early
dysbiosis in the development of polyps while the relative
abundance remained steady in both S1-S3 or HS1-HS3
stool samples, respectively (Fig. 5A). At the phylum level,
changes in Bacteroidetes were minimal in P1-P3. However, a generalized decrease in the Bacteroides genus in
P1-P3 was accompanied by a similar trend in H1–H3
(Fig. 5B).
We also observed a generalized reduction in Firmicutes and Bacteroidetes, but increases in Proteobacteria phyla, especially Alpha- and Gammaproteobacteria,

(See figure on next page.)
Fig. 3 A, B Unweighted pair group method with arithmetic mean (UPGMA). UPGMA-clustering trees based on weighted (A) and unweighted
(B) unifrac distances. C Linear discriminant analysis (LDA) Effect Size (LEfSe) analysis. A histogram of LDA scores was plotted to identify statistically
significant biomarkers and to reveal the dominant microorganisms in the groups (left panel). Taxonomic comparison between adjacent non-polyp
mucosa/stool samples. The taxonomic cladogram shows a comparison generated by GraPhlAn (Graphical Phylogenetic Analysis), representing
high-quality, compact visualizations of microbial genomes and metagenomes (right panel). Colors distinguish between Proteobacteria (blue),
Firmicutes (dark blue), Bacteroidetes (green), and Actinobacteria (red) phyla, while the intensity reflects the LDA score, an indicator of the effect sizes
of the significant differences. The size of the nodes correlates with their relative and logarithmically scaled abundances. Taxa were both statistically
significant (P < 0.05) and had an LDA Score > 4, considered a significant effect size
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Fig. 4 Machine learning findings. A The emerging ten most important bacteria in the machine learning models were compared between those
affected with polyps and controls using Wilcoxon test (ns: P > 0.05; *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001; ****: P ≤ 0.0001). B The emerging ten
most important species and families according to percentage variable importance, in the stool (left) and tissue (right) machine learning models,
respectively. C The correlation matrix showing distinguishing bacterial populations between patients with and without polyposis. D The RF model
was used to predict non-polyp mucosa from polyp tissue in affected individuals

were seen in P1–P3 groups compared to either H1–
H3, S1–S3 or HS1–HS3 groups, respectively suggesting that these changes may account for disease
progression over time (Fig. 5B). Interestingly, changes
in Lactobacillaceae in the P1–P3 samples were less
dramatic with no gradual decline compared to H1–H3

samples wherein, we observed an increase in H3 samples (Fig. 5B). Relative abundance of Lactobacillaceae
in the stool samples of FAP patients was less significant than either tissue polyps or adjacent non-polyp
mucosa (Fig. 5Bii). Since Fusobacterium has been
implicated in colon cancer progression, we observed
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Fig. 5 Bacterial communities in longitudinal study. Stool samples from patients: P1–P3, polyps in years 1–3; H1–H3, adjacent non-polyp tissue
in years 1–3; S1–S3 and HS1–HS3, stool samples from subjects with polyps (S1–S3) and healthy subjects (HS1–HS3) in years 1–3. A Bacterial
populations relative abundance in indicated groups. Arrows showing significant changes in indicated phyla. B Phylum and family abundance
heatmaps. The heatmaps displaying a relative abundance of dominant 35 bacterial populations among indicated samples, representing the (i)
phylum and (ii) family level in specified groups
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a substantial increase in Fusobacteria, especially Fusobacteriaceae in the P1-P3 samples compared to H1–
H3 wherein, the changes were less significant (Fig. 5B).
Our results showed a decline in alpha diversity
(Chao1) in the adenomatous tissues of year three FAP
patients (P3) compared to year one (P1) (Fig. 6A). In
contrast, adjacent non-polyp mucosa exhibited an
upward trend with higher variability in H3 samples
(Fig. 6A). However, when compared to P3 samples, a
dramatic shift in Simpson alpha diversity from low (P3)
to high (S3) with less variability was observed, suggesting distinct changes in the microbiota at these sites
(Fig. 6A). Our results exhibited significant alignment of
microbial communities in tissue or stool samples from
FAP patients in year 1. In year 2, stool samples started
to show separation from adenomatous tissues (Fig. 6B).
In year 3, microbial communities from adenomatous
tissues separated not only from the adjacent non-polyp
mucosa but, more importantly, from the stool samples
of FAP patients (Fig. 6B), reaffirming that polyp and
stool microbiota are very distinct.
Our longitudinal analyses also indicated that there
were several taxa with significant differences in years 1,
2, and 3. In year 1, the patients’ tissue and stool were
composed predominantly of Faecalibacterium (Fig. 6C).
On the other hand, Clostridium paraputrifcum, Bacteroidales S24_7, and Anaerostipes were higher in relative
abundance in year 2, while Proteobacteria, Enterobacteriaceae/ Enterobacteriales, E. coli_Shigella, Bacilli,
and Lactobacillales dominated year three patients’
samples (Fig. 6C). These results suggest that dysbiotic
changes in these groups of bacteria may be integral to
polyp evolution over time. Additional file 2: Fig. S2 is a
schematic of our major findings.
Taken together, our findings indicate that both local
(mucosa-related) and regional (stool-related) differences exist and that the longitudinal changes in the
microbiota at these sites may facilitate polyp evolution
over time.

Discussion
Familial adenomatous polyposis (FAP) is inherited as an
autosomal dominant trait, characterized by numerous
adenomas in the colon and rectum that progress to colorectal cancer by the 4th decade of life [12]. Most patients
with FAP harbor a germline mutation in the adenomatous polyposis coli (APC) gene. Evidence is emerging
for the role of microbiota in FAP based on pre-clinical
and clinical metagenomic studies along with pre-clinical
studies using gnotobiotic hosts [7]. A detailed exploration
of the spatio-temporal changes in the microbiome in the
adenomatous tissues versus the stool samples, however,
has not been achieved. We performed a high-throughput
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sequencing and bioinformatics analysis to characterize
the tissue and stool microbiota of the FAP patients and
compared them with healthy controls. The intent of the
current study was to investigate if differences exist in
microbiota composition between polyps and stool samples and whether the longitudinal changes in the microbiome may indicate susceptibility to developing colon
cancer later in life.
In previous studies, differences in community composition between cancerous tissues and surrounding areas
have led to a bacterial driver-passenger model for CRC
[13, 14] observed changes in rectal mucosal bacterial
communities of adenoma patients as well as in healthy
controls and suggested that rectal mucosal bacterial composition may reflect the presence of adenoma-specific
bacterial communities. We describe for the first time, differences in microbiota composition between polyps and
adjacent non-polyp mucosa and re-affirm that the bacterial populations in feces and mucosa are distinct and may,
in fact, differ in how they are enriched and/or distributed
over a period of time. Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria were the dominant phyla in
healthy controls, similar to previous studies on gut bacteria [15]. A large decrease in Firmicutes, Bacteroidetes,
and Actinobacteria coincided with the relative expansion
of Proteobacteria in the adenomatous or synchronous
tissues of FAP patients. These changes in Proteobacteria
phyla in tissues/polyps in years one to three were much
higher than those recorded in the stool. Proteobacteria
have been shown to be enriched in adenoma compared
with non-adenoma tissue from the same patient [16]
and compared with tissue from healthy volunteers [17].
They are reported as a major phylum in colonic biofilms
from FAP patients compared to healthy individuals [7].
Several larger studies reported significantly higher carriage or abundance of Proteobacteria in CRC [18, 19]. In
our cohort, as with the observed increased abundance of
Fusobacteria, these changes were not observed in patient
or control stool samples suggesting distinct evolution of
tissue and polyp microenvironment. Our observation of
increased abundance of Fusobacteria in polyp tissue over
time compared with healthy tissue or stool – where it
was barely detected, is consistent with an increase in the
prevalence and/or abundance of Fusobacterium nucleatum reported in the colorectal cancer tissue and fecal
samples compared to individuals with colorectal polyps
[20] and, may have important implications in CRC development in FAP. Fusobacteria is an adherent and invasive
Gram-negative anaerobic bacterium usually residing in
the oral cavity and associated with periodontal disease
[21]. It is a potential risk factor for CRC progression [22,
23] and a higher abundance of F. nucleatum in CRC is
associated with shorter survival [24]. Mechanistically,
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Fig. 6 Bacterial communities’ diversity in longitudinal study. A Alpha diversity (Chao1) and Simpson indices. B Principal coordinates analysis (PCoA).
Between-sample dissimilarities were measured by weighted (left panel) and unweighted (right panel) unifrac distances to assist the PCoA analysis.
Each symbol represents a sample. C Linear discriminant analysis (LDA) Effect Size (LEfSe) analysis in longitudinal study. Taxonomic comparison
between P1H1S1, P2H2S2, and P3H3S3 adjacent non-polyp mucosa/stool samples
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Fusobacterium induces the Wnt signaling through multiple mechanisms. Specifically, F. nucleatum interacts
with TLR4 inducing β-catenin phosphorylation by PAK1. The Wnt/β catenin pathway is also activated through
F. nucleatum-produced FadA adhesin binding to E-cadherin, resulting in up-regulation of Annexin A1 [23, 25].
Fusobacterium modulates CRC proliferation through
Toll-like receptor four signaling to MYD88, leading to
activation of the Nuclear Factor-κB (NF-κB) [26], resulting in increased TNF-α, IL-6, IL-8, and miR-135b. We
also observed mucosa-associated E. coli-Shigella cluster to be more prevalent in P1–P3 samples, which has
been shown to encode cyclomodulin, vital for mutational changes in colon crypt cells [27]. Thus, increases
in Fusobacteria and E. coli_Shigella clusters, especially
in year three cohorts, further delves into the significance
of mucosal dysbiosis in the evolution of CRC in FAP
patients.
As a member of the Clostridium leptum group, Faecalibacterium prausnitzii could represent the beneficial
commensal bacteria, and previous studies are consistent
with the anti-inflammatory properties of this bacterium
[28]. We observed a decline in Faecalibacterium belonging to Firmicutes phyla in the patients’ tissue and stool
polyps in years one to three (P1–P3) [29]. Faecalibacterium negatively correlates with inflammatory bowel disease activity and is relatively overexpressed in healthy
tissue compared with CRC-polyps [30]. Mechanistically,
this may be related to chemoprotective butyrate production, which correlates with dietary fiber intake [31].
Butyrate appears to induce tumor apoptosis through the
expression of E-Cadherin [32]. Faecalibacterium prausnitzii spp., which promote short-chain fatty acids production (SCFA), including butyrate, are decreased in
patients with advanced colorectal adenoma compared
with controls [33]. Interestingly, in a murine model, a
decline in other species including Bacteroides uniformis
and Bacteroides vulgatus in cohorts encompassing polyps, synchronous tissues, and stools, correlated with
disease progression [34]. Bacteroides uniformis utilizes
the O-glycans covalently attached to mammalian mucin
and serves as a mucin-degrader that predominantly colonizes the mucosal surfaces, thereby interacting with
the host [35]. A B. vulgatus strain was shown to protect
against E. coli-induced colitis in IL-2−/− mice [38], while
IL-10−/− mice mono-associated with pig isolates of B.
vulgatus had significantly reduced colitis-associated
colon tumor multiplicity compared with conventional
IL-10−/− mice [36]. Thus, a decline in the levels of these
species suggests that local microbiota disturbances may
accompany disease progression.
When comparing the alpha diversity indices among
groups using Student’s t-test, we observed that both
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chao1 and Simpson indices declined in P3. Specifically,
alpha diversity indices changed from low (P3) to high
(S3) with less variability, suggesting that distinct changes
in microbiome exist at these sites and that the development of adenomas/polyps may itself contribute towards
microbiota imbalances. When we further delved into
delineating the core microbiome at each site, we discovered ~ 1800 overlapping OTUs that were shared by the
four groups in a Venn diagram regardless of whether it
had high or low abundance. Yet, several unique OTUs
were also present at each site. This combination of unique
or overlapping core microbiomes may be integral to the
development of CRC in FAP patients. The community
structures of adenomatous/polyp tissues, when compared
with stool samples, revealed hierarchical clustering upon
PCoA analysis wherein, polyp and stool samples tended
to cluster separately in FAP patients, particularly in year
three (P3 vs. S3). These findings were further corroborated by ANOSIM data wherein, inter-group differences
were significantly greater than intra-group variation in
matched samples and by UPGMA clustering algorithm
that clearly revealed segregation of bacterial communities in the tissue and stool samples. These site-specific
alterations in the distribution of microbiota, whether
causal or consequential, may dictate the kinetics of adenoma development as a prelude to CRC. In particular,
we found that increased relative abundance of potential
opportunistic pathogens such as Alpha/beta-Proteobacteria, E. coli/Shigella, Fusobacteria, etc., which contribute
towards changes in intestinal homeostasis, might display
robust inflammatory infiltration and directly or indirectly
increase the risk of adenoma development.
We used machine learning to further provide insights
into which bacterial populations are unique to patients
with and without polyposis. The species that best discriminated between (stool from) subjects and controls
were Archaea, Micrococcus luteus, and Eubacterium hallii. Euryarchaeota, the principal Archaea phylum in the
intestinal microbiome, was one of the top 10 phyla in our
combined OTU analysis. Euryarchaeota is highly diverse
and includes methanogens, which in turn have been
shown to be depleted in CRC [37] coincident with a progressive increase in halophilic spp. in stool from controls,
adenoma then CRC. Furthermore, Archaea enrichment
has been shown to relate to changes in the alpha-diversity observed in CRC [38]. Our observations suggest that
perturbations in the Archaea subpopulation of the fecal
microbiome may indeed modulate adenoma progression
and may constitute useful biomarkers of syndromic adenomas. Another discriminant species in our ML analysis, Eubacterium hallii, distinguished stool from patients
with and without polyposis (controls). Eubacterium hallii is recognized as a SCFA producing commensal and is
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decreased in diverse disease states, including inflammatory bowel disease and colorectal cancer [39].
Eubacterium hallii has been shown to detoxify carcinogenic heterocyclic aromatic amines present in processed
meats [40]; its suppression, along with other SCFA producing species, has been implicated mechanistically in
the relationship of high animal fat consumption in gut
inflammatory and neoplastic processes [41]. Specifically,
E. hallii has been proposed as a candidate next-generation probiotic [42].
The significance of Micrcoccus luteus is unclear; M.
luteus is a well-described opportunistic pathogen usually in the context of immunocompromised hosts and
has, to date, not been implicated in colorectal adenoma
or cancer.
Thus, the realization that the microbiome modulates
colorectal cancer risk introduces the possibility of altering the microbiome to change the risk of malignancy.
Probiotics including Lactobacillus and Bifidobacterium
have been shown to decrease adenoma formation in
murine models of FAP [43, 44]. The mechanisms underlying the antitumor effects of probiotics include modulation of inflammatory pathways including NF-κB and
downregulation of β-catenin; mechanisms that our
observations suggest are active in the progression of adenomatous polyp evolution in our population. Specifically,
for example, Lactobacillus supplementation has been
shown to increase Roseburia in the ApcMin/ + mouse
model reversing one of the characteristics of polyp evolution observed in our study [44]. The polyp-microbial
interrelationships we observed in patients with FAP may
be interpreted in the context of potential pre- and probiotic therapy, including a putative role for E. hallii.
Our study has several limitations. Given the rarity
of the underlying diagnosis of pediatric pre-colectomy
FAP, accrual of a robust cohort was difficult. Maintaining regular surveillance and sampling as well as identifying and recruiting a suitable control was challenging.
Accordingly, we could not obtain all planned samples
over the three-year study period in any of our patients.
This does not detract, however, from the validity of
observations between different sample groups during
the same year. Recent genetic testing was not available in all subjects, this could account for some of the
subjects having been tested several years ago, with less
sensitive testing modalities, reported as APC mutation
negative. Our choice of controls inherently presented
a challenge insofar as cohabiting, unaffected, samegender individuals would be preferred but was unfeasible in view of siblings, if any, in most instances being
either younger and untested, or older and not cohabiting, we therefore consciously chose cohabitation, being
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the stronger determinant of similarity [45], and therefore necessarily the study design favored the inclusion of unaffected parents skewing the mean age of
the control population. Ultimately, we recognize that
any choice of control poses potential pitfalls as many
factors [46, 47] influence the intestinal microbiome
and therefore any realistic control cannot be perfectly
matched. This may have a bearing on the observed differences between subject and control stool. Similarly
with the challenge of control samples, we understand
the small sample sizes might limit our interpretation of our results. However, we minimized the error
in our study due to effect size, by (1) adopting robust
comparison of between and within sample groups for
PERMANOVA analyses [48]; (2) ensuring the samples satisfied the t-test assumptions [49]; (3) ensuring
the LEfSe analyses are performed by ranking based on
magnitude of variation and not statistical significance
[11].
As implied above, the principal limitation of our
study is the attrition in samples in years two and 3. We
have therefore adopted a strategy to separately analyze
year one where the bulk of the samples are, and then we
examined the findings from longitudinal analyses of the
small subset that have longitudinal samples. Our present work provided the first step into the understanding
of the microbiome shifts due to FAP, and future work
could be performed with more samples to provide further insights.
Our study further highlights the limitation of stoolsampling strategies in defining the polyp microenvironment in adenomatous polyposis and by
extrapolation sporadic polyp. Although some interrelatedness between polyp, healthy mucosa, and stool
microbiome was apparent, it is exceedingly challenging to correlate polyp microenvironment changes from
stool samples. Future research may focus on whether
the detection of certain bacterial concentrations within
stool or biopsied polyps could serve as adjuncts to current screening modalities to help identify higher-risk
patients.

Conclusions
We conclude that in children with FAP, the adenomas
represent a devolution toward a more simplified bacterial community with key components having established pro-oncogenic characteristics when compared
with uninvolved mucosa and stool and that the longitudinal changes in the microbiome at these sites even
though limited in sample sizes, may facilitate polyp
evolution over time.
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